Pace, acceleration, and precision are the name of the game
Security and privacy within biotech are critical points of consideration and discussion as the industry continues to innovate at speed, and it is such aspects that are central to today’s podcast with Zach Powers, chief information security officer at Benchling, the R&D cloud platform for the biotech industry.
From autonomous therapeutic systems to CRISPR-based gene editing, from wearables to brain-computer interfaces, and from Generative AI to quantum technology – pace, acceleration, and importantly precision are the name of the game, and web editor Nicole Raleigh and Powers discuss the importance of new tech stacks and the ongoing struggle with the amount of data that is being created, managing terabytes of data and automated actions.
When it comes to best practice, how biotech can borrow from banking is also explored.
Adopting a common approach to modern technology foundations being equally crucial, Powers explains that the AI solutions being offered to companies are still software, and modern approaches to software security work ‘just fine’; it is not the media-overblown security risk some believe it to be, he says.
And on trust and hesitancy, and moving from on-premise to cloud based solutions, Powers notes that European biotechs remain yet hesitant to adopt the latter, ‘borders’ being one aspect of this – tune in to hear more, and why on-prem often poses a greater security risk.
You can listen to episode 130a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, acast, Stitcher, and Podbean.
